Kura Oncology (NASDAQ:KURA) Earns “Market Outperform” Rating from Citizens Jmp

Kura Oncology (NASDAQ:KURA)‘s stock had its “market outperform” rating reiterated by stock analysts at Citizens Jmp in a research report issued on Monday,Benzinga reports. They currently have a $24.00 price target on the stock. Citizens Jmp’s price target suggests a potential upside of 164.70% from the company’s current price.

KURA has been the topic of several other reports. Lake Street Capital assumed coverage on shares of Kura Oncology in a report on Tuesday, April 14th. They set a “buy” rating and a $23.00 price target on the stock. Wedbush decreased their price objective on shares of Kura Oncology from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, March 6th. Wells Fargo & Company set a $24.00 target price on Kura Oncology in a research report on Thursday, June 4th. CLSA set a $24.00 target price on Kura Oncology in a research note on Thursday, June 4th. Finally, Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a report on Thursday, May 28th. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Kura Oncology has an average rating of “Moderate Buy” and an average target price of $25.46.

Kura Oncology Trading Up 0.2%

NASDAQ:KURA traded up $0.02 during midday trading on Monday, hitting $9.07. 136,351 shares of the company traded hands, compared to its average volume of 1,571,797. The firm has a market capitalization of $804.88 million, a P/E ratio of -2.71 and a beta of 0.36. The firm’s fifty day moving average is $9.31 and its 200-day moving average is $9.31. Kura Oncology has a 12-month low of $5.45 and a 12-month high of $12.49. The company has a current ratio of 6.15, a quick ratio of 6.14 and a debt-to-equity ratio of 0.09.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.05. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. The company had revenue of $18.27 million during the quarter, compared to analyst estimates of $25.97 million. On average, sell-side analysts predict that Kura Oncology will post -3.47 EPS for the current year.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Kura Oncology by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock worth $333,000 after acquiring an additional 2,977 shares during the period. Strs Ohio purchased a new stake in shares of Kura Oncology in the first quarter valued at approximately $143,000. Legal & General Group Plc boosted its holdings in shares of Kura Oncology by 35.1% in the second quarter. Legal & General Group Plc now owns 72,910 shares of the company’s stock valued at $421,000 after purchasing an additional 18,930 shares during the period. Rhumbline Advisers grew its stake in Kura Oncology by 13.0% in the second quarter. Rhumbline Advisers now owns 118,896 shares of the company’s stock worth $686,000 after purchasing an additional 13,690 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in Kura Oncology by 244.5% in the second quarter. American Century Companies Inc. now owns 232,752 shares of the company’s stock worth $1,343,000 after purchasing an additional 165,189 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.